Autonomic Function is Associated with Fitness Level in HIV-Infected Individuals

Morgan H Kocher1, MS, ATC, Ronald K Hetzler1*, PhD, FACSM, Cecilia M Shikuma2, MD, Iris F Kimura1,2, PhD, ATC, PT, Cris D Stickley1, PhD, ATC, CSCS, Rachel A Lindsey3, PhD, ATC, Beau K Nakamoto2,4, MD, PhD, Dominic C Chow2, MD, MPH, PhD

1Department of Kinesiology and Rehabilitation Science, College of Education, University of Hawaii at Manoa, Honolulu, USA
2Hawaii Center for AIDS, Department of Medicine, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, USA
3Math and Science Department, Kapiolani Community College, Honolulu, HI, USA
4Department of Neurology, Straub Clinic & Hospital, Honolulu, HI, USA

*Corresponding author: Dr. Ronald Hetzler, 1337 Lower Campus Road, PE/A 231, Honolulu, HI 96822 USA, Tel: (808) 956-3802; Fax: (808) 956-7976; E-mail: hetzler@hawaii.edu

Cite this article: Hetzler R. Autonomic Function is Associated with Fitness Level in HIV-Infected Individuals. J Aids Hiv. 2015, 1(1): 005.

Abstract

Background: Cardiovascular fitness can improve autonomic function (AF) in human immunodeficiency virus (HIV)-infected individuals.

Methods: Cross-sectional study investigating relationship between AF and cardiovascular fitness in HIV+ individuals on antiretroviral therapy. Participants’ (n=29) maximal oxygen consumption (VO\textsubscript{2MAX}) were assessed by graded exercise test and scaled allometrically, then divided into tertiles by fitness level (Unfit, Low-fit, and Moderately-fit). Heart rate variability (HRV) and the Autonomic Reflex Screen were used to assess AF.

Results: Median VO\textsubscript{2MAX} were 104.9, 130.5, and 150.2 mL·kg\textsuperscript{-0.67}·min\textsuperscript{-1} for Unfit (n=10), Low-fit (n=10), and Moderately-fit (n=9) groups respectively (p<0.05). Positive correlations were found between VO\textsubscript{2MAX} and HRV (Spearman’s rho range 0.383 to 0.553) were found. Quantitative Sudomotor Axon Reflex Test (QSART) Distal Leg volumes was lower in Unfit compared to Low-fit (p=0.007) and Moderately-fit groups (p=0.018). Unfit QSART total volumes was lower than Moderately-fit (p=0.014).

Conclusion: A positive relationship existed between AF and fitness levels. HIV+ individuals could benefit from improved fitness.

Keywords: VO\textsubscript{2MAX}; Heart Rate Variability; Autonomic Reflex Screen; Autonomic Nervous System; HIV

Abbreviations

HIV: Human Immunodeficiency Virus;
AIDS: Acquired Immunodeficiency Syndrome;
CVD: Cardiovascular Disease;
Introduction

Autonomic dysfunction is a common co-morbidity of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) [1,2]. Decreased autonomic function is linked to increased risk of cardiovascular disease (CVD) and all-cause mortality [3,4]. This dysfunction is often characterized by increased sympathetic activity, and decreased parasympathetic activity and heart rate variability (HRV) [5,6].

Cardiovascular fitness has a positive correlation with time- and frequency-domain measures of HRV in healthy populations, regardless of training level [7]. Autonomic function improved with habitual exercise and improved cardiovascular fitness in patients with cardiovascular disease and diabetes [5,7,8]. Autonomic function has been related to physical fitness levels of HIV-positive individuals on ART by Spierer et al. [9], who reported no significant difference in high frequency (HF) power (indicating parasympathetic function) between fit HIV-positive individuals and healthy fit individuals but a significant difference in HF power between fit and unfit HIV-positive individuals. However, the HIV-positive groups investigated by Spierer et al. had a large difference in oxygen uptake between fit and unfit groups (41.4±2.4 vs. 26.9±4.4 mL·kg⁻¹·min⁻¹, respectively) [9].

The purpose of this study was to explore the relationship between unfit, low and moderate aerobic fitness levels and autonomic function in an HIV-positive population receiving stable ART. Time and frequency-domains of HRV were determined; and, unlike previous studies on HIV-positive populations, autonomic function was also assessed using the Autonomic Reflex Screen (ARS), which included the Quantitative Sudomotor Axon Reflex Test (QSART), Heart Rate Deep Breathing (HR\textsubscript{dep}), and Valsalva tests [10,11]. The ARS is useful in diagnosing autonomic failure and has clinical and prognostic implications.

Methods

Participants were HIV-positive individuals on six months of stable ART medication. Exclusionary criteria were: known cardiac disease, arrhythmia, active substance abuse, pregnancy, and absolute contraindications for exercise testing as outlined by the American College of Sports Medicine (ACSM) [12]. Participants signed a consent form approved by the university’s institutional review board, and this protocol was in compliance with the Helsinki Declaration.

VO\textsubscript{2max} testing

All VO\textsubscript{2max} data were collected in single 90-minute sessions supervised by an attending physician. Participants warmed up on a cycle ergometer (Model 818 E, Monark, Stockholm, Sweden) for five minutes. The initial workload was 50 Watts and increased by 12.5 Watts every minute. Maximal effort was based on ACSM’s criteria for maximal exercise testing [12]. Maximal oxygen consumption was assessed with a Max Ila
metabolic cart (AEI technologies, Naperville, IL), using standard open circuit spirometry techniques. Electrocardiogram (ECG) output, blood pressure, heart rate (HR), and ratings of perceived exertion(2) were monitored. Blood lactate concentration was determined pre- and seven minutes post-exercise using a Lactate Plus Lactate Meter (Nova Biomedical Co., Waltham, MA). Absolute maximal oxygen uptake (L・min−1) was ratio-scaled using body mass (mL・kg−1・min−1) and allometrically-scaled (mL・kg−0.67・min−1) to eliminate the influence of body mass [14]. Participants were divided into tertiles according to their allometrically-scaled VO2MAX: Unfit (<115 mL・kg−0.67・min−1), Low-fit (115-140 mL・kg−0.67・min−1), and Moderately-fit (>140 mL・kg−0.67・min−1).

**Autonomic testing**

Three areas of autonomic function were tested using the ARS: sudomotor,cardiovagal, and adrenergic [15]. All three components of the ARS are considered valid and reliable measures of autonomic function [10,13,16]. Additionally, time- and frequency-domain measures of HRV were extrapolated from a resting ECG using Kubios Heart Rate Variability Software Version 2.0 (University of Kuopio, Kuopio, Finland).

**Sudomotor Quantitative Sudomotor Axon Reflex Test (QSART)**

Four sites on the participant’s left side were tested: dorsal surface of the foot, medial surface of the distal leg (5 cm proximal to medial malleoli), lateral surface of proximal leg (5 cm distal to head of fibula), and the two-thirds of the distance distal to head of fibula), and the two-thirds of the distance between the stimulated sites was determined using WR Testworks Suite 2.1 (WR Testworks, Stillwater, MN).

**Heart rate deep breathing (cardiovagal testing)**

After completion of the QSART, a five-minute baseline ECG was recorded and participants subsequently followed a visual cue to breathe at six breaths per minute for eight breaths. Mean difference in HR was determined from the five largest consecutive variations between maximum and minimum heart rates. The test was repeated at two-minute intervals until two satisfactory curves were recorded. Chest expansion, HR, and beat-to-beat BP were measured by a Colin Pilot 700 (Colin Medical Instruments Corp., San Antonio, TX) equipped with an Atlas digital to analogue converter box (WR Testworks, Stillwater, MN). Data were recorded on a computer using WR Testworks Suite 2.1 [17,18].

**Valsalva test (adrenergic testing)**

After a five-minute rest, participants were tilted to a 20 degree head-up angle, and blew a "bugle" maintaining an expiratory pressure of 40 mmHg for 15 seconds followed by a three-minute silent rest. The procedure was repeated until two satisfactory BP curves were obtained. Expiratory pressure, beat-to-beat BP, and HR were recorded [17,18].

**Composite autonomic scoring scale**

The Composite Autonomic Scoring Scale (CASS) was compiled from the results of the ARS. Autonomic testing data (Valsalva, HRDB, and QSART) were combined to form the CASS [11]. This 10-point scale measures autonomic failure divided into three sections: adrenergic (4 points), cardiovagal (3 points), and sudomotor (3 points). Participants with a score of 1 to 3 have mild autonomic failure, a score of 4 to 6 indicates moderate failure, and a score greater than 7 is indicative of severe autonomic failure [11].

**Heart rate variability**

Interbeat intervals (RR) were imported into Kubios HRV Software for time- and frequency-domain analysis. Low level artifact correction was applied if necessary and the sample length was set to five minutes. Trend components were removed using a Smooth n Priors method. Interpolation of RR series was set at 4 Hz. Window width for fast Fourier transformation was set at 512 seconds with window overlap set at 50% [13,19].

Parasympathetic and sympathetic modulations of the heart were quantified by assessing the power spectral density of interbeat interval oscillations occurring from 0.04 to 0.40 Hz, thought to originate from autonomic modulations of the sinus node. The low-frequency power (LF; 0.04 to 0.15 Hz) represents both sympathetic and parasympathetic control, and high-frequency power (HF; 0.15 to 0.40 Hz) reflects parasympathetic modulation. The LF/HF power ratio attempts to remove the parasympathetic influences, thereby representing primarily sympathetic activity [13,19].

Time-domain parameters, based on simple statistical measures of variability, address the magnitude of variability and provide information about the vagal (parasympathetic) modulation of the heart, with higher variability generally reflecting greater parasympathetic modulation. Reduced HRV in individuals with symptomatic autonomic neuropathy has prognostic implications for future cardiovascular disease events in the HIV-positive populations [20,21]. Time-domain measures included the standard deviation of the normal RR intervals (SDNN), the root of the mean squares of successive RR differences (rMSSD), the number of RR intervals greater than fifty milliseconds different from its predecessor (NN50) and the percentage of RR intervals greater than fifty milliseconds different from its predecessor (pNN50). Overall HRV is reflected by SDNN and rMSSD measures while pNN50 measures HRV's
short term components, with SDNN being the most representative parameter of HRV [13,19].

Statistical analysis

Data were analyzed using SPSS Statistical Analysis Software Version 20 (IBM, Armonk, New York, USA). Statistical significance was set at a $p<0.05$ probability level. A Kolmogorov-Smirnov test was used to determine that the data were not normally distributed. Spearman's Rank Correlation Coefficients were calculated between measures of fitness, heart rate variability, ARS, and body mass. Kruskal-Wallis One-Way ANOVAs were used to determine the main effects for differences between groups and post-hoc analyses were performed using multiple Mann-Whitney U tests with the Holm's sequential Bonferroni adjustment to determine differences between the Unfit, Low-fit, and Moderately-fit groups.

Results

Participants

This study included 29 participants (2 female, 27 male) between 22 and 63 years old (median 49.9, Q1 44.1, Q3 52.6 years). Median CD4 count was 500 cells/mm$^3$ (Q1 333, Q3 681), with only 4 participants (14%) having a CD4 count $<$200 cells/mm$^3$. Viral load was undetectable in the majority of participants (86%), with only 4 participants (14%) having a CD4 count $<$200 cells/mm$^3$. Overall, 20.7% (6 of 29) of participants were current smokers, 30% (3 of 10) in the Unfit group, 10% (1 of 10) in the Low-fit group and 11.1% (2 of 9) in the Moderately-fit group. Six of the non-smoking participants had previously smoked, time since quitting ranged from 1 week to 30 years, median 5.25 years. In the Unfit group, 2 participants (20%) were on statins; in the Low-fit group, 4 participants (40%) were on statins; and in the Moderately-fit group, 3 participants (33.3%) were on statins. Overall, 31% of participants (9 of 29) were on statins. None of the participants had diabetes. Overall body fat percentage was 28% (Q1 21.1%, Q3 31.5%), the Unfit group was highest at 29% (Q1 23.25%, Q3 37%), and the Moderately-fit group was lowest at 20% (Q1 16.5%, Q3 27.5%). The median for the Low-fit group was 28% (Q1 23.5%, Q3 32.25%) (Table 1). Body fat percentage was significantly different between Unfit and Moderately-fit groups ($p=0.011$) and approached significance between Unfit and Low-fit groups ($p=0.057$). Fat free mass (Table 1) was significantly different between Moderately-fit and Unfit ($p=0.018$) and Low-fit groups ($p=0.011$). According to ACSM normative VO$_{2\text{max}}$ values for age and gender, the Unfit group was in the 8th percentile, the Low-fit group was in the 29th percentile, and the Moderately-fit group was in the 52nd percentile [12]. All groups had significantly different VO$_{2\text{max}}$ values using unscaled, ratio-scaled, and allometrically-scaled measures ($p<0.0001$ for all, see Table 1). Resting HR was significantly different between Unfit and Moderately-fit groups post-exercise ($p=0.011$).

No participants had a total CASS score over three, indicating no moderate or severe autonomic dysfunction. Low levels of autonomic dysfunction existed in 20% of the Low-fit, 40% of the Moderately-fit, and 60% of the Unfit group. However, there was no correlation between CASS score and HF power ($\rho=0.058$, $p=0.766$), or CASS score and LF/HF ratio ($\rho=0.176$, $p=0.360$). The QSWEAT results were adjusted using the formulas provided by Sletten et al. [22] in order to compare them to established Mayo Clinic QSART normative means [22,23]. For indices of autonomic function, significant differences were seen in QSART distal leg volume ($p=0.008$), and total QSART volume ($p=0.034$). Distal Leg sweat volume was significantly different between Unfit and Low-fit ($p=0.007$) and Unfit and Moderately-fit groups ($p=0.018$), but not between Low-fit and Moderately-fit groups ($p=0.935$). Total Volume was significantly different between Unfit and Moderately-fit groups ($p=0.014$). These values can be seen in Figure 1. Significant moderate positive correlations were also present between allometrically-scaled VO$_{2\text{max}}$ and two measures from the QSART: Distal Leg Volume (Spearman’s $\rho=0.553$, $p=0.002$), and Total Volume ($\rho=0.490$, $p=0.007$).

Although correlations were noted between allometrically-scaled VO$_{2\text{max}}$ and time-domain measures of HRV, no differences were seen between fitness level groups in time- and frequency-domains. Group medians (Q1, Q3), and $p$ values for all autonomic variables (both time- and frequency-domains) can be seen in Table 2. All participants fell within two standard deviations of the HR$_{\text{NN}}$ normative values for HIV-positive participants established by the Mayo Clinic and WR Medical. Allometrically-scaled VO$_{2\text{max}}$ had significant moderate positive correlations with the time-domain measures of SDNN ($\rho=0.383$, $p=0.041$), rMSSD ($\rho=0.403$, $p=0.030$), NN50 ($\rho=0.387$, $p=0.038$), and pNN50 ($\rho=0.412$, $p=0.026$). No significant correlations between frequency-domain measures of HRV and allometrically-scaled VO$_{2\text{max}}$ were found. Significant moderate positive correlations were present between allometrically-scaled VO$_{2\text{max}}$ and two QSART measures: Distal Leg Volume ($\rho=0.553$, $p=0.002$), and Total Volume ($\rho=0.490$, $p=0.007$). A significant positive correlation existed between HF power and the adrenergic portion of the CASS ($\rho=0.447$, $p=0.015$). Significant correlations were also found between total cholesterol and LF and HF power, as well as LF/HF ratio ($\rho=0.681$, 0.681, and -0.686 respectively, $p<0.001$ for all). The only significant correlations between the CASS composites and time domain measures of HRV were significant negative correlations between the Adrenergic portion of the CASS and SDNN and RMSSD ($\rho=-0.376$, $p=0.044$ for both).
### Table 1

<table>
<thead>
<tr>
<th>Continuous variables</th>
<th>Unfit Group (n=10)</th>
<th>Low-fit Group (n=10)</th>
<th>Moderately Fit Group (n=9)</th>
<th>Sig. 2-Tailed (p)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>49.7 (44.4, 52.4)</td>
<td>48.7 (44.2, 54.7)</td>
<td>49.9 (42.8, 52.6)</td>
<td>0.253</td>
</tr>
<tr>
<td>Sedentary, n, %</td>
<td>7, 70</td>
<td>8, 80</td>
<td>5, 56</td>
<td></td>
</tr>
<tr>
<td>Body Mass, kg</td>
<td>79.5 (67.5, 89.75)</td>
<td>81.5 (74.5, 89.25)</td>
<td>76 (69, 85.5)</td>
<td>0.287</td>
</tr>
<tr>
<td>Body Fat, %</td>
<td>29 (23.25, 37)</td>
<td>28 (23.8, 32.25)</td>
<td>20 (16.5, 27.3)</td>
<td>0.030*</td>
</tr>
<tr>
<td>Fat Free Mass, kg</td>
<td>53.55 (48.88, 60)</td>
<td>58.75 (52.33, 63.43)</td>
<td>59.8 (53.75, 65.1)</td>
<td>0.031*</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.7 (23.8, 29.5)</td>
<td>27.1 (23.4, 30.0)</td>
<td>24.3 (23.7, 25.8)</td>
<td>0.419</td>
</tr>
<tr>
<td>CD4 count, cells/mm³</td>
<td>192.5 (161.3, 205.8)</td>
<td>156 (148.8, 177)</td>
<td>170 (166, 213)</td>
<td>0.473</td>
</tr>
<tr>
<td>Years HIV+</td>
<td>16.5 (7, 19.3)</td>
<td>15.5 (6.8, 20.3)</td>
<td>16.0 (10.0, 21.0)</td>
<td>0.700</td>
</tr>
<tr>
<td>Undetectable Viral Load ≤48 cells/mm³, n, %</td>
<td>9 (90)</td>
<td>8 (80)</td>
<td>7 (78)</td>
<td>-</td>
</tr>
<tr>
<td>Cholesterol, mg/dL</td>
<td>192.5 (161.3, 205.8)</td>
<td>156 (149.8, 177.0)</td>
<td>170.0 (166.0, 213.0)</td>
<td>0.530</td>
</tr>
<tr>
<td>Resting HR, BPM</td>
<td>66.5 (59.25, 68.25)</td>
<td>58.5 (53.5, 66)</td>
<td>58 (48, 60.5)</td>
<td>0.214</td>
</tr>
<tr>
<td>Resting SBP, mmHG</td>
<td>119 (110, 138.5)</td>
<td>112.5 (103.5, 133.3)</td>
<td>125 (115, 140)</td>
<td>0.672</td>
</tr>
<tr>
<td>Estimated Max HR, BPM</td>
<td>174.2 (172.2, 177.7)</td>
<td>174.9 (170.5, 177.8)</td>
<td>174.1 (172.1, 178.7)</td>
<td>0.310</td>
</tr>
<tr>
<td>Absolute VO_max, L/min⁻¹</td>
<td>2.1 (1.7, 2.2)</td>
<td>2.4 (2.1, 2.5)</td>
<td>3.0 (2.4, 3.1)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Ratio-scaled VO_max, mL/kg⁻¹·min⁻¹</td>
<td>24 (23.5, 30)</td>
<td>29.5 (28.0, 32.3)</td>
<td>36.0 (34.0, 39.0)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Allometrically-scaled VO_max, mL·kg⁻⁶·min⁻¹</td>
<td>104.9 (98.3, 117.0)</td>
<td>130.5 (117.4, 135.3)</td>
<td>150.2 (141.4, 161)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Peak HR, BPM</td>
<td>173.6 (171.8, 177.7)</td>
<td>174.3 (170.3, 177)</td>
<td>173.5 (171.7, 178.2)</td>
<td>0.099</td>
</tr>
<tr>
<td>Post exercise Lactate, mmol/L</td>
<td>8.5 (5.75, 9)</td>
<td>9.5 (7.8, 12.5)</td>
<td>9 (6.1, 11.5)</td>
<td>0.279</td>
</tr>
<tr>
<td>Sedentary (n, %)</td>
<td>7, 70</td>
<td>8, 80</td>
<td>5, 56</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th>Continuous variables</th>
<th>Unfit Group (n=10)</th>
<th>Low-fit Group (n=10)</th>
<th>Moderately Fit Group (n=9)</th>
<th>Sig. 2-Tailed (p)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autonomic Reflex Screen</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR_DBD Average Difference, BPM</td>
<td>13.0 (8.0, 15.5)</td>
<td>12.5 (10.0, 15.8)</td>
<td>15.0 (8.0, 20.0)</td>
<td>0.318</td>
</tr>
<tr>
<td>HR_RMD Percentile Rank, %</td>
<td>20.5 (9.0, 49.0)</td>
<td>21.5 (11.8, 53.3)</td>
<td>25.0 (11.5, 67.0)</td>
<td>0.875</td>
</tr>
<tr>
<td>Valsalva Test Greatest HR Ratio, BPM</td>
<td>2.0 (2.0, 2.3)</td>
<td>2.0 (1.8, 2.0)</td>
<td>2.0 (2.0, 2.5)</td>
<td>0.514</td>
</tr>
<tr>
<td>Valsalva Test Percentile Rank, %</td>
<td>57.5 (31.8, 85.3)</td>
<td>38.5 (27, 51.3)</td>
<td>70.0 (49.0, 94.0)</td>
<td>0.763</td>
</tr>
<tr>
<td><strong>Time-Domain Measures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDNN, ms</td>
<td>34.5 (31.5, 42.3)</td>
<td>30.0 (18.3, 52.5)</td>
<td>40.0 (29.5, 52.0)</td>
<td>0.223</td>
</tr>
<tr>
<td>rMSSD, ms</td>
<td>28.5 (21.5, 39.5)</td>
<td>27.5 (12.8, 48.8)</td>
<td>43.0 (27.5, 58.0)</td>
<td>0.283</td>
</tr>
<tr>
<td>NN50, count</td>
<td>22.5 (7.8, 69.3)</td>
<td>23.0 (1.8, 75.5)</td>
<td>39.0 (24.0, 105.0)</td>
<td>0.283</td>
</tr>
<tr>
<td>pNN50, %</td>
<td>7.0 (2.8, 21.3)</td>
<td>8.0 (0.8, 27.5)</td>
<td>16.0 (8.0, 45.0)</td>
<td>0.240</td>
</tr>
<tr>
<td><strong>Frequency-Domain Measures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Power, ms²⁴⁷</td>
<td>907.5 (694.8, 1371.8)</td>
<td>791.0 (310.8, 2120.2)</td>
<td>1718.0 (744.0, 2724.0)</td>
<td>0.153</td>
</tr>
<tr>
<td>LF Power, ms²⁴⁷</td>
<td>478.5 (252.0, 1073.7)</td>
<td>348.5 (186.3, 849.3)</td>
<td>955.0 (291.5, 1934.5)</td>
<td>0.427</td>
</tr>
<tr>
<td>HF Power, ms²⁴⁷</td>
<td>56.5 (45.5, 81.5)</td>
<td>65.5 (51.3, 82.3)</td>
<td>70.0 (55.0, 78.5)</td>
<td>0.244</td>
</tr>
<tr>
<td>LF/HF Power Ratio</td>
<td>1.0 (1.0, 4.3)</td>
<td>2.0 (1.0, 5.0)</td>
<td>2.0 (1.0, 3.5)</td>
<td>0.342</td>
</tr>
</tbody>
</table>

---

Cite this article: Hetzler R. Autonomic Function is Associated with Fitness Level in HIV-Infected Individuals. J J Aids Hiv. 2015, 1(1): 005.
Discussion

The significant positive correlations between VO\textsubscript{2\text{MAX}} and the time-domain variables of HRV (Spearman’s rho range 0.383 to 0.412, \(p<0.05\)) indicate that even low or moderate increases in aerobic fitness contribute to increased HRV. The correlation between HF power and allometrically-scaled VO\textsubscript{2\text{MAX}} approached significance (rho=0.348, \(p=0.055\)), indicating a positive trend in the relationship between VO\textsubscript{2\text{MAX}} and parasympathetic tone. However, there were no significant differences between groups for time- or frequency-domain measures of HRV. Allometrically-scaled VO\textsubscript{2\text{MAX}} was significantly correlated with both Distal Leg sweat volume and Total volume, which increased significantly with increased fitness in HIV-positive participants (\(p=0.050\)). When viewed with the correlations between fitness level and HRV time-domain measures, this difference in sweat volumes support a relationship between autonomic function and cardiovascular fitness levels for a largely sedentary cohort of HIV-positive participants on ART. The lack of correlation between CASS and HF and LF/HF power suggest that the two methods measure different aspects of autonomic function.

Overall, parasympathetic function in the current study was lower and sympathetic function was higher compared to Buchheit and Gindre’s fit participants, who defined “fit” as having a VO\textsubscript{2\text{MAX}} above 50 mL·kg\(^{-1}\)·min\(^{-1}\); greater than all but one participant in the current study [7,15]. The distribution of VO\textsubscript{2\text{MAX}} scores in the current study was fairly narrow, with approximately half of participants falling below the 20\% percentile of ACSM norms for a healthy population [15]. The indicators of HRV from the current study predominately fall below the values for the fit groups from the aforementioned studies, but are similar to values from their unfit groups [7,9].

Unlike HRV, sweat production is regulated predominately by the sympathetic nervous system and QSART dysfunction is often indicative of small nerve fiber neuropathy [10]. Total Volume and Distal Leg QSART volume differed significantly between groups. Most sample sites, including Total Volume, had higher percentiles of Mayo Clinic norms in the Moderately-fit group and decreased percentiles in the Unfit group (Figure 1). Therefore, greater physical fitness levels in sedentary HIV-positive participants were associated with improved sweat responses and peripheral autonomic function. It should be noted that the participants were acclimatized to a tropical environment, which may make comparisons against the Mayo Clinic norms problematic. Although not measured in the present study, this could be an indicator of impaired glucose tolerance in the Unfit group as compared to the Moderately-fit group [24].

Spierer et al.’s study of unfit and fit HIV-positive and -negative groups revealed a relationship between fitness level and cardiovascular/autonomic health [9]. All three fitness groups from the current study had lower HF power than the HIV-pos-

Figure 1. QSART values by Site and Fitness Level

A unique aspect in the current study was allometrically-scaling fitness levels to remove the confounding influence of body mass on the scaled variable (VO\textsubscript{2\text{MAX}}), which resulted in five participants being assigned to a different group than if ratio-scaled. Nevill [25] stated that “simple ratio standards ‘over-scale’ by converting the positive correlation between the physiological performance variable and the body size variable to a negative one.” In the current study ratio scaling resulted in a significant negative correlation with body mass (rho=-0.41, \(p=0.022\)), overcorrecting for body mass and failing to eliminate the influence of body mass on VO\textsubscript{2\text{MAX}}. It has been previously shown that when comparing fitness levels, if VO\textsubscript{2} is left unscaled (L·min\(^{-1}\)), larger individuals will have a higher VO\textsubscript{2\text{MAX}} (as seen in the present study with a correlation with body mass rho=0.511, \(p=0.003\)) [26]. Allometric scaling (mL·kg\(^{-0.67}\)·min\(^{-1}\)) helps correct for these influences. The allometric exponent validated by Heil et al. (0.67) was used in the current study to remove the confounding effects of body mass on VO\textsubscript{2\text{MAX}} [14]. Vanderburgh has previously suggested that the “litmus test” for controlling for body mass using different scaling methods is that the scaled variable should have a correlation with body mass that approaches zero [27]. The efficacy of allometric scaling can be seen by the reduced correlation between body mass and VO\textsubscript{2\text{MAX}} which approached zero (rho=-0.08, \(p=0.653\)), thus supporting the use of allometric scaling.

The relationship between allometrically-scaled VO\textsubscript{2\text{MAX}}
time-domain measures and sweat volumes existed despite the fact that the majority of the participants were sedentary (less than 30 minutes of moderate physical activity three times a week for the past 3 months). Buchheit and Gindre previously reported a positive relationship between indices of HRV and VO_{2max} in a healthy population, but that training load had a limited effect on HRV [7]. A sedentary lifestyle has been reported to desensitize the baroreflex response, resulting in a decrease in vagal tone and a shift towards sympathetic activity [9]. Since an active lifestyle is related to increased levels of physical fitness, HIV-positive individuals would likely improve autonomic function by adopting an active lifestyle.

Askggaard et al. reported a significant inverse correlations of total cholesterol with multiple time-domain measures (rMSSD r =-0.26, pNN50 r=-0.24) [28]. The authors speculated that “hypercholesterolemia causes more damage to the autonomic nervous system in HIV-positive patients than in controls.” In contrast, the current study found significant correlation between total cholesterol and HF power, and an inverse relationship with LF/HF ratio (rho=0.681, and -0.686 respectively, p<0.001 for all), but not with time-domain measures of HRV. These findings suggest a need for future study as suggested by Askggaard et al [1].

Limitations to the current study included the cross-sectional design (which didn’t allow for comparison of autonomic function and fitness levels over time), the lack of control group or controlling for lipodystrophy and dyslipidemia, and the small range of fitness levels. This narrow range of fitness levels or the HRV measures used may have contributed to the lack of differences in HRV found between groups. Despite these limitations, significant differences in QSART volumes were found between groups.

**Conclusion**

Positive correlations between fitness levels and time-domain measures of HRV coupled with differences in the total sweat volume from the QSART indicate a relationship between aerobic fitness and autonomic function in low to moderately fit HIV-positive individuals on a stable ART regimen. An active lifestyle that increase or maintain aerobic fitness could potentially ameliorate symptoms of autonomic dysfunction in HIV-positive individuals.

**Conflicts of Interest**

There were no conflicts of interests with any of the authors.

**Acknowledgements**

This study was funded by NIH grants U54RR026136, U54MD007584, R01HL095135 (CMS), and K23 HL088981 (DC). No authors had conflicts of interests to disclose. No external reviews were used in editing this article for publication. The authors would like to thank Rachel Lindsey, Katie Sullivan, Nancy Hanks, and Rebecca Romine for their contributions to the study. Some technical assistance for troubleshooting the autonomic cart was provided by the Mayo Clinic.

**References**


11. Low PA, Benaroch EE, and Ovid Technologies I. Clinical autonomic disorders. Lippincott Williams & Wilkins;


